Guedj N - Search Results

1

Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks.

Vaquero J, Guedj N, Clapéron A, Nguyen Ho-Bouldoires TH, Paradis V, Fouassier L. Vaquero J, et al. Among authors: guedj n. J Hepatol. 2017 Feb;66(2):424-441. doi: 10.1016/j.jhep.2016.09.010. Epub 2016 Sep 26. J Hepatol. 2017. PMID: 27686679 Review.

2

Global proteomic analysis of microdissected cirrhotic nodules reveals significant biomarkers associated with clonal expansion.

Guedj N, Dargere D, Degos F, Janneau JL, Vidaud D, Belghiti J, Bedossa P, Paradis V. Guedj N, et al. Lab Invest. 2006 Sep;86(9):951-8. doi: 10.1038/labinvest.3700450. Epub 2006 Jul 17. Lab Invest. 2006. PMID: 16847432 Free article.

3

Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P, Belghiti J. Paradis V, et al. Among authors: guedj n. Hepatology. 2009 Mar;49(3):851-9. doi: 10.1002/hep.22734. Hepatology. 2009. PMID: 19115377

4

[Prognosis factors of cholangiocarcinoma: contribution of recent molecular biology tools].

Malouf G, Dreyer C, Guedj N, Paradis V, Degos F, Belghiti J, Le Tourneau C, Faivre S, Raymond E. Malouf G, et al. Among authors: guedj n. Bull Cancer. 2009 Apr;96(4):405-15. doi: 10.1684/bdc.2008.0780. Bull Cancer. 2009. PMID: 19357015 Review. French.

5

Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas.

Guedj N, Zhan Q, Perigny M, Rautou PE, Degos F, Belghiti J, Farges O, Bedossa P, Paradis V. Guedj N, et al. J Hepatol. 2009 Jul;51(1):93-101. doi: 10.1016/j.jhep.2009.03.017. Epub 2009 Apr 25. J Hepatol. 2009. PMID: 19446907

6

[Pathology of cholangiocarcinoma].

Guedj N, Bedossa P, Paradis V. Guedj N, et al. Ann Pathol. 2010 Dec;30(6):455-63. doi: 10.1016/j.annpat.2010.10.004. Epub 2010 Nov 27. Ann Pathol. 2010. PMID: 21167432 Review. French.

7

Loss of EBP50 stimulates EGFR activity to induce EMT phenotypic features in biliary cancer cells.

Clapéron A, Guedj N, Mergey M, Vignjevic D, Desbois-Mouthon C, Boissan M, Saubaméa B, Paradis V, Housset C, Fouassier L. Clapéron A, et al. Among authors: guedj n. Oncogene. 2012 Mar 15;31(11):1376-88. doi: 10.1038/onc.2011.334. Epub 2011 Aug 8. Oncogene. 2012. PMID: 21822312

8

EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition.

Clapéron A, Mergey M, Nguyen Ho-Bouldoires TH, Vignjevic D, Wendum D, Chrétien Y, Merabtene F, Frazao A, Paradis V, Housset C, Guedj N, Fouassier L. Clapéron A, et al. Among authors: guedj n. J Hepatol. 2014 Aug;61(2):325-32. doi: 10.1016/j.jhep.2014.03.033. Epub 2014 Apr 3. J Hepatol. 2014. PMID: 24704591

9

Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy.

Dreyer C, Sablin MP, Bouattour M, Neuzillet C, Ronot M, Dokmak S, Belghiti J, Guedj N, Paradis V, Raymond E, Faivre S. Dreyer C, et al. Among authors: guedj n. World J Hepatol. 2015 Apr 28;7(6):910-5. doi: 10.4254/wjh.v7.i6.910. World J Hepatol. 2015. PMID: 25937868 Free PMC article.

10

Loss of ezrin in human intrahepatic cholangiocarcinoma is associated with ectopic expression of E-cadherin.

Guedj N, Vaquero J, Clapéron A, Mergey M, Chrétien Y, Paradis V, Fouassier L. Guedj N, et al. Histopathology. 2016 Aug;69(2):211-21. doi: 10.1111/his.12931. Epub 2016 Mar 1. Histopathology. 2016. PMID: 26791814

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

76 results

Search Page

Filters